A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Durvalumab (Primary) ; MEDI 9090 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MedImmune
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2016 Planned number of patients changed from 30 to 36.
- 27 Sep 2016 New trial record